Medicinal Products

China's drug registration system classifies medicines into chemical drugs, biologics, and traditional Chinese medicines (TCM), each with its own category tiers based on novelty and prior approval status.

For foreign applicants, two primary pathways apply:

• Imported Drug Registration (IDR)

  • Class 5.1 - Original drugs marketed overseas but not yet marketed in China.
  • Class 5.2 - Generic drugs produced and marketed overseas.

  Both classes of IDR require a local legal representative (Domestic Responsible Person, or DRP) and submission of the full dossier to NMPA, including overseas approval evidence.

• New Drug Application (NDA/BLA) - for drugs without prior global approval, requiring clinical data from trials with Chinese patient participation or an accepted Multi-Regional Clinical Trial (MRCT).

Foreign Marketing Authorization Holders (MAHs) must appoint a qualified China-based legal entity as DRP. The DRP bears joint liability with the foreign MAH for product quality and safety and must be named in the product's package insert.

NMPA offers four formally codified accelerated pathways, often called "green channels", for products meeting specific criteria:

• Breakthrough Therapy Designation -for drugs showing a significant clinical advantage over existing therapies for serious diseases. Enables rolling NDA submission and frequent CDE engagement, substantially compressing timelines.
• Conditional Approval -for drugs addressing urgent unmet clinical needs where full pivotal data is not yet complete. Marketing is conditional on completing confirmatory trials by a specified deadline; failure can result in license revocation.
• Priority Review - targets a ~130 working-day technical review timeline (versus ~200 days standard) for drugs treating serious or life-threatening conditions, rare diseases, and urgently needed both domestic and/or overseas drugs.
• Special Approval -for drugs urgently needed in declared public health emergencies.

Selecting the right pathway early in development is critical, as each carries distinct data requirements and post-approval commitments.

Yes. NMPA accepts overseas clinical trial data for drug registration in China, provided two core conditions are met:

• Ethnic consistency - data must demonstrate that the drug's safety and efficacy profile is applicable to the Chinese population. If ethnic sensitivity is a concern, additional China-specific bridging data may be required.
• Data integrity - all data must comply with ICH GCP (E6) and relevant NMPA data integrity requirements.

Multi-Regional Clinical Trials (MRCTs) with Chinese patient sites are strongly preferred by NMPA and are the dominant strategy for imported drugs. MRCTs allow simultaneous global and China submissions, reducing time-to-market and avoiding duplicative standalone China trials.

For sponsors managing human genetic resources (HGR) from Chinese subjects, HGRAC approval from the National Health Commission is required before exporting biological samples or data - a compliance step that must be built into clinical planning.

China's Regulatory framework now provides two forms of IP-adjacent protection: market exclusivity and data exclusivity, which are distinct from patent rights:

• Data Exclusivity (up to 6 years) - protects undisclosed clinical trial data submitted in support of marketing authorization for innovative chemical entities. Prevents competitors from relying on that proprietary data to obtain approval during the protection period.
• Market Exclusivity for Pediatric Drugs (up to 2 years) - applies to eligible new pediatric medicines, including novel dosage forms, specifications, or expanded indications for children.
• Market Exclusivity for Orphan Drugs (up to 7 years) - applies to qualifying rare disease treatments. Conditional on the MAH maintaining a guaranteed drug supply, exclusivity may be terminated if supply obligations are not met.

These protections should be factored into R&D planning and licensing strategy. Companies focused on pediatric or rare disease therapeutics benefit most, as the commercial protection period effectively extends the window to recoup development investment.

China's CMC requirements are among the most technically demanding globally and apply to both the drug substance (API) and drug product. A complete CMC dossier must include:

• Drug substance: full synthesis or fermentation/expression description, in-process controls, characterization, specifications, and stability data.
• Drug product: formulation development rationale, manufacturing process with validation data, container-closure system, and shelf-life studies.
• Post-approval changes to manufacturing are tightly regulated. Major changes require prior NMPA approval; minor changes require filing. Any unapproved changes constitute a compliance violation.

Contract and segmented manufacturing (splitting production stages across multiple sites) is permitted for innovative drugs and those in urgent clinical need, provided the MAH maintains full quality oversight. For high-risk products such as sterile drugs, on-site supervisory inspections of contract manufacturers are required at least annually.

All manufacturing sites, domestic and foreign, are subject to NMPA GMP inspection before and after approval.

Post-approval obligations in China are extensive and ongoing. The MAH bears full lifecycle accountability for product safety and quality, regardless of whether manufacturing is outsourced.

Core pharmacovigilance (PV) obligations include:

• Implementing a comprehensive PV system aligned with China's Good Pharmacovigilance Practices (GVP), covering adverse reaction monitoring, signal detection, and risk management.
• Cooperating with distributors and medical institutions in adverse event reporting and risk control.
• Submitting periodic safety update reports and expedited reports for serious unexpected adverse reactions on NMPA-specified timelines.

For conditionally approved products, completing confirmatory trials by the agreed deadline is a legal obligation; failure triggers a formal NMPA warning and, ultimately, license revocation. Priority Review and Breakthrough approvals typically also carry Phase IV study commitments.

Post-market evaluation is linked to re-registration. MAHs must continuously assess benefit-risk profiles; inadequate evaluations may result in non-renewal at product expiry.

Registration approval by NMPA grants legal authorization to sell a drug in China, but commercial viability depends heavily on inclusion in the National Basic Medical Insurance (NBMI) catalog, administered by the National Healthcare Security Administration (NHSA).

Key points for Regulatory and market access teams:

• NBMI inclusion provides access to China's vast insured population. Without it, most patients in the public healthcare system cannot afford innovative drugs at market price.
• Annual catalog reviews allow newly approved drugs, including innovative drugs, orphan drugs, pediatric medicines, and oncology products, to apply for listing. Inclusion negotiations involve price discussions with the NHSA.
• Health Technology Assessment (HTA) dossiers are increasingly expected as part of the listing process, requiring clinical and pharmacoeconomic evidence.
• NBMI strategy should be planned in parallel with NMPA registration, not after. Delays in reimbursement listing can significantly delay real-world market uptake even after approval.

Regulatory teams should coordinate with market access, medical affairs, and health economics functions early to align the evidence generation plan with both NMPA registration and NBMI listing requirements.